Angiogenic and immunomodulatory biomarkers in axitinib-treated patients (pts) with advanced renal cell carcinoma (aRCC).

被引：1
|
作者：
Rini, Brian I.
Escudier, Bernard
Murphy, Danielle
Wang, Panpan
Tarazi, Jamal Christo
Motzer, Robert J.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Univ Paris Saclay, Gustave Roussy, Med Oncol, Villejuif, France
[3] Pfizer Oncol, La Jolla, CA USA
[4] Pfizer Oncol, Shanghai, Peoples R China
[5] Pfizer Oncol, San Diego, CA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期
关键词：
D O I：
10.1200/JCO.2019.37.7_suppl.614
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
614
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Clinical and economic outcomes associated with sequential treatment in patients with advanced renal cell carcinoma (aRCC).
    Regan, Meredith M.
    McDermott, David F.
    Atkins, Michael B.
    Ambavane, Apoorva
    Yang, Shuo
    Rao, Sumati
    Michaelson, M. Dror
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Pembrolizumab plus axitinib for the treatment of advanced renal cell carcinoma
    Spisarova, Martina
    Melichar, Bohuslav
    Vitaskova, Denisa
    Studentova, Hana
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (07) : 693 - 703
  • [43] Targeted treatments in advanced renal cell carcinoma: focus on axitinib
    Verzoni, Elena
    Grassi, Paolo
    Testa, Isabella
    Iacovelli, Roberto
    Biondani, Pamela
    Garanzini, Enrico
    De Braud, Filippo
    Procopio, Giuseppe
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 107 - 116
  • [44] Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
    Ansari, Jawaher
    Hussain, Syed A.
    Ansari, Asif
    Glaholm, John
    BIOLOGICS-TARGETS & THERAPY, 2013, 7 : 39 - 46
  • [45] Identification of biomarkers in pazopanib treated patients with renal cell carcinoma
    Pick, Amy M.
    Cochrane, Zara Risoldi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2013, 2 (02) : 117 - 118
  • [46] Impact of axitinib therapy management on adverse event (AE) resolution/improvement (Res/Imp) among advanced renal cell carcinoma (aRCC) patients (Pts) receiving first-line (1L) axitinib plus checkpoint inhibitor (CPI) therapy
    Huynh, L.
    Du, S. S.
    Chang, R.
    Pi, S.
    Sundaresan, S.
    Duh, M. S.
    Thomaidou, D.
    Zanotti, G.
    Zakharia, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S1404 - S1405
  • [47] Subgroup analysis from JAVELIN Renal 101: Outcomes for avelumab plus axitinib (A plus Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Choueiri, Toni K.
    Motzer, Robert J.
    Campbell, Matthew T.
    Alekseev, Boris Y.
    Uemura, Motohide
    Kollmannsberger, Christian K.
    Gravis, Gwenaelle
    Bjarnason, Georg A.
    Gurney, Howard
    Chung, Jinsoo
    Haanen, John B. A. G.
    Rini, Brian I.
    Larkin, James M. G.
    Schmidinger, Manuela
    Nole, Franco
    Chudnovsky, Aleksander
    Huang, Bo
    Hariharan, Subramanian
    di Pietro, Alessandra
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [48] THE COMPARATIVE COST-EFFECTIVENESS OF CABOZANTINIB, EVEROLIMUS AND AXITINIB IN ADVANCED RENAL CELL CARCINOMA (ARCC) AFTER FAILURE OF PRIOR THERAPY: SCOTTISH PERSPECTIVE
    Lister, J.
    Vataire, A.
    Amzal, B.
    Dinet, J.
    Meng, J.
    Karcher, H.
    Gabriel, S.
    VALUE IN HEALTH, 2017, 20 (09) : A440 - A440
  • [49] Updated efficacy of lenvatinib (LEN) plus pembrolizumab (PEMBRO) vs sunitinib (SUN) in patients (pts) with advanced renal cell carcinoma (aRCC) in the CLEAR study
    Porta, C. G.
    Eto, M.
    Motzer, R. J.
    De Giorgi, U. F. F.
    Buchler, T.
    Basappa, N. S.
    Mendez Vidal, M. J.
    Tjulandin, S.
    Park, S. H.
    Melichar, B.
    Hutson, T. E.
    Alemany, C.
    McGregor, B.
    He, C. S.
    Perini, R.
    Mody, K.
    McKenzie, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1205 - +
  • [50] Efficacy outcomes of nivolumab plus cabozantinib versus pembrolizumab plus axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
    McGregor, Bradley Alexander
    Geynisman, Daniel M.
    Burotto, Mauricio
    Porta, Camillo
    Rodriguez, Cristina Suarez
    Bourlon, Maria Teresa
    Barata, Pedro C.
    Gulati, Shuchi
    Stwalley, Brian
    Del Tejo, Viviana
    Du, Ella X.
    Wu, Aozhou
    Chin, Andi
    Betts, Keith A.
    Huo, Stephen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345